Oxaliplatin

Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head and Neck Squamous Cell Carcinoma at ASCO 2024

Retrieved on: 
Donnerstag, Mai 23, 2024
Immune tolerance, Prognosis, Master, ILT4, Flow cytometry, Pembrolizumab, Anemia, WT, HPV, Colorectal cancer, NK, University, Clinical trial, PFS, Therapy, Neoplasm, Disease, EGFR, Safety, SAN, Head, ILT2, Irinotecan, PD-1, Growth, Bevacizumab, Cancer, Incidence, ASCO, Associate, MHC, Consultant, Woman, Society, Fatigue, BRAF, Cetuximab, Tizona, Immunotherapy, Oxaliplatin, DCR, Combination therapy, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a privately held, clinical-stage company developing cancer immunotherapies, today announced first-in-human Phase 1b clinical data of TTX-080, a novel, first-in-class, antibody targeting HLA-G, in patients with metastatic colorectal cancer (mCRC) and locally advanced/metastatic head and neck squamous cell carcinoma (mHNSCC). The preliminary data will be presented during a poster session on June 1, 2024, at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 in Chicago, IL.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a privately held, clinical-stage company developing cancer immunotherapies, today announced first-in-human Phase 1b clinical data of TTX-080, a novel, first-in-class, antibody targeting HLA-G, in patients with metastatic colorectal cancer (mCRC) and locally advanced/metastatic head and neck squamous cell carcinoma (mHNSCC).
  • The preliminary data will be presented during a poster session on June 1, 2024, at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 in Chicago, IL.
  • “Metastatic colorectal cancer is a global health issue, affecting men and women equally and with rising incidence among young adults.
  • “These Phase 1b clinical results boost our confidence that TTX-080 in combination with cetuximab may improve clinical outcomes in patients with biomarker-defined advanced colorectal cancer and head and neck squamous cell carcinoma,” said Swami Murugappan, M.D., Ph.D., Consulting Chief Medical Officer at Tizona Therapeutics.

Innate Pharma Reports First Quarter 2024 Business Update and Financial Results

Retrieved on: 
Dienstag, Mai 14, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, EV, Drug, Relapse, PDX, MF, FDA, Form, CD20, Carcinoma, Amyloidosis, Euronext Paris, Acute myeloid leukemia, Randomized controlled trial, B-ALL, NK, AACR, Telephone, ADC, Neoplasm, PD-1, ATM, NHL, CRT, Acute lymphoblastic leukemia, GEMOX, Food, NSCLC, EVP, ADS, IPHA, Cancer, ASCO, Poster, BCMA, Oxaliplatin, AstraZeneca, Takeda, Bone marrow, IPH, Lung cancer, Prospectus, PTCL, Spacecraft, CD123, Abstract, Webcast, Pharmaceutical industry

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the quarter ending March 31, 2024.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the quarter ending March 31, 2024.
  • Top-line results in MF patients will be presented at the ASCO Annual Meeting 2024 being held May 31 – June 4 in Chicago.
  • Cash, cash equivalents and financial assets of the Company amounted to €113.9 million as of March 31, 2024.
  • Cash, cash equivalents and financial assets as of March 31, 2024 do not include the €4.0 million payment to be received from Sanofi.

Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting

Retrieved on: 
Montag, Mai 13, 2024
Patient, Ministry, NMPA, MHLW, CHMP, European Medicines Agency, HER2, Ministry of Health, Dicarboxylic acid, Safety, Zolbetuximab, Cisplatin, BCR, Prostate, GEJ, Research, Prostate cancer, EMA, Cancer, ASCO, Leuprorelin, Abstract, Astellas Pharma, Society, Committee, Oxaliplatin, Quality of life, Annual general meeting, Vaccine

TOKYO, May 13, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new research from across its innovative portfolio of approved and investigational cancer therapies during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 - June 4. A total of 16 abstracts will be presented, including new data from pivotal trials supporting ongoing regulatory reviews. The volume of data being presented by Astellas reinforces its commitment to changing the course of cancer treatment through targeted therapies for hard-to-treat cancers like prostate, urothelial, and gastric/gastroesophageal junction (GEJ) cancers.

Key Points: 
  • TOKYO, May 13, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new research from across its innovative portfolio of approved and investigational cancer therapies during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 - June 4.
  • A total of 16 abstracts will be presented, including new data from pivotal trials supporting ongoing regulatory reviews.
  • The volume of data being presented by Astellas reinforces its commitment to changing the course of cancer treatment through targeted therapies for hard-to-treat cancers like prostate, urothelial, and gastric/gastroesophageal junction (GEJ) cancers.
  • "The data at ASCO demonstrate the strength and breadth of our growing oncology portfolio and provide new insights into our transformative therapies for patients living with some of the most devastating cancers.

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance

Retrieved on: 
Mittwoch, April 24, 2024
Core, FDA, Ipsen, Food, Pancreatic cancer, Oxaliplatin, RNA, Webcast, Patent, ADC, District court, Fluorouracil, Patient, Paragraph, Dicarboxylic acid, DSM-IV codes, Therapy, CER1, Growth, Pharmaceutical industry

“The delivery of our strategic plan continues to be evidenced by a strong top line, supported by the success of the growth platforms and the increased contribution of the new medicines.

Key Points: 
  • “The delivery of our strategic plan continues to be evidenced by a strong top line, supported by the success of the growth platforms and the increased contribution of the new medicines.
  • Moreover, the pipeline continues to deliver, illustrated this quarter by the regulatory approval in the U.S. of Onivyde as a first-line treatment for pancreatic cancer.
  • “This year marks a pivotal period for our growth plans, with the launches of four new medicines or indications.
  • In April 2024, Ipsen announced an exclusive global licensing agreement for STRO-003, an antibody-drug conjugate (ADC) targeting the ROR1 tumor antigen.

Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025

Retrieved on: 
Montag, April 22, 2024
MSN, Safety, Protein-bound paclitaxel, OTCQB, Prognosis, Survival, Oxaliplatin, Doctor of Philosophy, Therapy, Patient, Fluorouracil, Dicarboxylic acid, Data analysis, PBLA, Pharmaceutical industry

MINNEAPOLIS, April 22, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the interim data analysis for its ongoing ASPIRE trial is now expected to be available as soon as Q1 2025.

Key Points: 
  • MINNEAPOLIS, April 22, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the interim data analysis for its ongoing ASPIRE trial is now expected to be available as soon as Q1 2025.
  • As of the latest assessment, less than half of the required events for the interim analysis have occurred.
  • "The early indications from the ASPIRE trial support this belief, and we remain committed to advancing this important study and look forward to sharing the interim results in March 2025."
  • Panbela will continue to monitor the progress of the ASPIRE trial and provide updates as appropriate.

Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study

Retrieved on: 
Montag, April 15, 2024
Research, FDA, Genetics, Clinical Trials, Stem Cells, Biotechnology, Pharmaceutical, Health, Science, Oncology, Phase, Safety, DLBCL, Risk, Food, European Commission, ROG, Survival, Oxaliplatin, Roche, Aggressive lymphoma, Disease, Rituximab, Patient, Civil service commission, GemOx, Diagnosis, B-cell lymphoma, Pharmaceutical industry

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the Phase III STARGLO study met its primary endpoint of overall survival.

Key Points: 
  • Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the Phase III STARGLO study met its primary endpoint of overall survival.
  • Safety of the combination appeared consistent with the known safety profiles of the individual medicines.
  • The data will be submitted to health authorities and shared at an upcoming medical meeting.
  • Columvi is a CD20xCD3 T-cell engaging bispecific antibody designed to be off-the-shelf and ready for infusion, so patients can start treatment soon after diagnosis.

Onchilles Pharma Presents at AACR 2024 New Preclinical Data for N17350 and N17465 Demonstrating the Potential for Potent and Tumor-Selective Treatment

Retrieved on: 
Dienstag, April 9, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Cancer, Pharma, Blood, Doxorubicin, Oxaliplatin, Breast, San Diego Convention Center, CDX, Prostate cancer, Death domain, Therapy, Immunogenic cell death, Patient, Neoplasm, ICD, Lung, Toxicity, AACR, Immune system, Carboplatin, Ovarian cancer, CD95, Vaccine

N17350 and N17465 are novel first-in-class oncology programs that harness the potent efficacy of the innate immune system and have the potential to become a major new treatment modality for a wide range of cancer types.

Key Points: 
  • N17350 and N17465 are novel first-in-class oncology programs that harness the potent efficacy of the innate immune system and have the potential to become a major new treatment modality for a wide range of cancer types.
  • Lev Becker, Ph.D., Scientific Founder, Onchilles Pharma, said, “We are excited to unveil systemically delivered N17465 that has the potential to redefine the treatment of solid tumors.
  • The data presented today demonstrate that N17465 exhibits potent and tumor-selective efficacy, mobilizes the immune system for anti-tumor immunity, and produces durable responses in mouse models as a monotherapy.
  • We are confident that N17350 and N17465 represent a novel class of molecules that could become the new foundation of cancer treatment.

GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer

Retrieved on: 
Freitag, April 19, 2024
FDA, Total, Colorectal cancer, Mutation, Immunology, Lung cancer, Priority review, NMPA, National Medical Products Administration, Cetuximab, Progression-free survival, New Drug Application, Irinotecan, Oxaliplatin, Recurrence, RAS, CRC, ESMO, Medicine, ASCO, Canadian International Council, Disease, Incidence, Patient, Liver, Peritoneum, Food and Drug Administration, BTD, Lung, Death, Biology, Clinical trial, EGFR, Therapy, Cancer, NSCLC, Breakthrough therapy, Prevalence, Pharmaceutical industry

"We appreciate the FDA's recognition of GFH925' efficacy and safety profile, as this is our first global phase III monotherapy study in treating advanced stage CRC.

Key Points: 
  • "We appreciate the FDA's recognition of GFH925' efficacy and safety profile, as this is our first global phase III monotherapy study in treating advanced stage CRC.
  • We believe the approval of our proposed trial design highlights the potential of GFH925 monotherapy in this indication, thus bringing more therapeutic options and clinical benefits to the patients.
  • Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver, International Journal of Molecular Science, Mar.
  • Disease Burden of Total and Early-Onset Colorectal Cancer in China from 1990 to 2019 and Predictions of Cancer Incidence and Mortality, Clinical Epidemiology, Feb. 2023
    4.

Summary of opinion: Onivyde pegylated liposomal (previously known as Onivyde), 21/03/2024 Positive

Retrieved on: 
Mittwoch, April 3, 2024
European Commission, Civil service commission, Patient, Irinotecan, Oxaliplatin, Committee, Dicarboxylic acid, Medication package insert, Marketing, CHMP, Pancreas

On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Onivyde pegylated liposomal.

Key Points: 
  • On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Onivyde pegylated liposomal.
  • The marketing authorisation holder for this medicinal product is Les Laboratoires Servier.
  • Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.
  • 1New text in bold

Summary of opinion: Onivyde pegylated liposomal (previously known as Onivyde), 21/03/2024 Positive

Retrieved on: 
Mittwoch, April 3, 2024
European Commission, Civil service commission, Patient, Irinotecan, Oxaliplatin, Committee, Dicarboxylic acid, Medication package insert, Marketing, CHMP, Pancreas

On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Onivyde pegylated liposomal.

Key Points: 
  • On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Onivyde pegylated liposomal.
  • The marketing authorisation holder for this medicinal product is Les Laboratoires Servier.
  • Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.
  • 1New text in bold